📊 TVRD Key Takeaways
Is Tvardi Therapeutics, Inc. (TVRD) a Good Investment?
Tvardi Therapeutics is in severe financial distress with revenue collapsing 66% YoY to $2.6M while operating losses widen to -$26.7M. The company is burning $24.5M in free cash flow annually with only ~$20.7M in cash reserves, providing less than one year of runway at current burn rates. Absent a dramatic operational or clinical turnaround, the fundamental business model appears broken.
Why Buy Tvardi Therapeutics, Inc. Stock? TVRD Key Strengths
- Strong liquidity position with current ratio of 2.86x and $20.7M cash
- No long-term debt provides financial flexibility
- Positive stockholders' equity of $20.9M reduces immediate solvency risk
TVRD Stock Risks: Tvardi Therapeutics, Inc. Investment Risks
- Revenue collapsed 66% YoY indicating loss of product traction or market access
- Operating cash burn of $23.5M annually with minimal cash runway remaining
- Extreme operating losses (-$26.7M) and negative margins (-1041% operating margin) demonstrate non-viable unit economics
- Biotech/pharma sector context suggests potential pipeline failure or clinical setback
Key Metrics to Watch
- Quarterly revenue trend and stabilization
- Monthly cash burn rate and cash runway timeline
- Operating expense reduction initiatives and restructuring progress
- New product launches or partnership announcements that could restore revenue growth
Tvardi Therapeutics, Inc. (TVRD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.86x current ratio provides a solid financial cushion.
TVRD Profit Margin, ROE & Profitability Analysis
TVRD vs Healthcare Sector: How Tvardi Therapeutics, Inc. Compares
How Tvardi Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tvardi Therapeutics, Inc. Stock Overvalued? TVRD Valuation Analysis 2026
Based on fundamental analysis, Tvardi Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tvardi Therapeutics, Inc. Balance Sheet: TVRD Debt, Cash & Liquidity
TVRD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tvardi Therapeutics, Inc.'s revenue has declined by 69% over the 5-year period, indicating business contraction. The most recent EPS of $-11.42 indicates the company is currently unprofitable.
TVRD Revenue Growth, EPS Growth & YoY Performance
TVRD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $2.1M | -$4.9M | $-3.22 |
| Q3 2024 | $2.6M | -$12.5M | $-0.23 |
| Q2 2024 | $991.0K | -$20.0M | $-0.37 |
| Q1 2024 | $2.1M | -$26.7M | $-0.49 |
| Q3 2023 | $4.9M | -$4.2M | $-0.43 |
| Q2 2023 | $6.9M | -$4.2M | $-0.08 |
| Q1 2023 | $4.8M | -$26.7M | $-0.49 |
| Q3 2022 | $10.8M | -$1.0M | $-0.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tvardi Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TVRD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tvardi Therapeutics, Inc. (CIK: 0001346830)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TVRD
What is the AI rating for TVRD?
Tvardi Therapeutics, Inc. (TVRD) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TVRD's key strengths?
Claude: Strong liquidity position with current ratio of 2.86x and $20.7M cash. No long-term debt provides financial flexibility.
What are the risks of investing in TVRD?
Claude: Revenue collapsed 66% YoY indicating loss of product traction or market access. Operating cash burn of $23.5M annually with minimal cash runway remaining.
What is TVRD's revenue and growth?
Tvardi Therapeutics, Inc. reported revenue of $2.6M.
Does TVRD pay dividends?
Tvardi Therapeutics, Inc. does not currently pay dividends.
Where can I find TVRD SEC filings?
Official SEC filings for Tvardi Therapeutics, Inc. (CIK: 0001346830) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TVRD's EPS?
Tvardi Therapeutics, Inc. has a diluted EPS of $-3.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is TVRD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Tvardi Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is TVRD stock overvalued or undervalued?
Valuation metrics for TVRD: ROE of -87.0% (sector avg: 15%), net margin of -709.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy TVRD stock in 2026?
Our dual AI analysis gives Tvardi Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TVRD's free cash flow?
Tvardi Therapeutics, Inc.'s operating cash flow is $-23.5M, with capital expenditures of $1.0M. FCF margin is -955.4%.
How does TVRD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -709.0% (avg: 12%), ROE -87.0% (avg: 15%), current ratio 2.86 (avg: 2).